Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeisVac-C + Pediacel + Infanrix + Prevenar-13 + Menitorix + Priorix + Rotarix
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This combination represents a comprehensive pediatric immunization regimen consisting of multiple vaccines targeting bacterial and viral pathogens. It was specifically utilized in a clinical trial conducted by the University of Oxford, titled "Impact of BCG on MenC Vaccine Immunogenicity" (NCT01535820), to investigate whether the Bacille Calmette-Guérin (BCG) vaccine enhances the immune response to the Meningococcal group C (MenC) vaccine in healthy infants. The regimen includes vaccines against Neisseria meningitidis serogroup C (NeisVac-C, Menitorix), diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Pediacel, Infanrix), Streptococcus pneumoniae (Prevenar-13), measles, mumps, rubella (Priorix), and rotavirus (Rotarix). These vaccines function by inducing active immunity through the presentation of toxoids, inactivated viruses, recombinant proteins, and conjugated polysaccharides, as well as live-attenuated viral strains.
02
Targets
Diphtheria toxinMV (Measles virus)Mumps virus antigenNeisseria meningitidis group C capsular polysaccharidePV3 (Sabin) (Poliovirus type 3 antigen)RVA (Rotavirus A)CPS (Streptococcus pneumoniae capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on NeisVac-C + Pediacel + Infanrix + Prevenar-13 + Menitorix + Priorix + Rotarix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeisVac-C + Pediacel + Infanrix + Prevenar-13 + Menitorix + Priorix + Rotarix.